How may ramucirumab help improve treatment outcome for patients with gastrointestinal cancers?

Ming Huang Chen, Sheng Nan Lu, Chien Hung Chen, Peng Chan Lin, Jeng Kai Jiang, Yulia D’yachkova, Mariusz Lukanowski, Rebecca Cheng, Li Tzong Chen

研究成果: Review article同行評審

6 引文 斯高帕斯(Scopus)

摘要

GI cancers are characterized by high recurrence rates and a dismal prognosis and there is an urgent need for new therapeutic approaches. This is a narrative review designed to provide a summary of the efficacy as measured by overall survival, progression free survival, and safety data from phase 3 randomized controlled GI clinical trials of ramucirumab including those from important pre-specified patient subgroups and evidence from real clinical practice worldwide. Quality of life (QOL) is discussed where data are available. Our aim was to summarize the efficacy and safety of ramucirumab in the treatment of GI cancers using these existing published data with a view to demonstrating how ramucirumab may help improve treatment outcome for patients with GI cancers. The data indicate that ramucirumab is efficacious, safe, and tolerable across the intent-to-treat patient populations as a whole and across several pre-specified subgroups, even those whose disease is traditionally more difficult to treat. Furthermore, survival outcomes observed in real-world clinical practice demonstrate similar data from phase 3 clinical trials even in patients with complications, suggesting that the benefits of ramucirumab translate in actual clinical practice.

原文English
文章編號3536
期刊Cancers
13
發行號14
DOIs
出版狀態Published - 2021 7月 2

All Science Journal Classification (ASJC) codes

  • 腫瘤科
  • 癌症研究

指紋

深入研究「How may ramucirumab help improve treatment outcome for patients with gastrointestinal cancers?」主題。共同形成了獨特的指紋。

引用此